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Received December 23, 2015; accepted March 24, 2016AbstractBackground: Glioblastoma multiforme (GBM) is the most lethal type of adult brain cancer and performs outrageous growth and resistance
regardless of adjuvant chemotherapies, eventually contributing to tumor recurrence and poor outcomes. Considering the common heterogeneity
of cancer cells, the imbalanced regulatory mechanism could be switched on/off and contribute to drug resistance. Moreover, the subpopulation of
GBM cells was recently discovered to share similar phenotypes with neural stem cells. These cancer stem cells (CSCs) promote the potency of
tumor initiation. As a result, targeting of glioma stem cells has become the dominant way of improving the therapeutic outcome against GBM
and extending the life span of patients. Among the biomarkers of CSCs, CD-133 (prominin-1) has been known to effectively isolate CSCs from
cancer population, including GBM; however, the underlying mechanism of how stemness genes manipulate CSC-associated phenotypes, such as
tumor initiation and relapse, is still unclear.
Methods: Tumorigenicity, drug resistance and embryonic stem cell markers were examined in primary CD133-positive (CD133þ) GBM cells
and CD133þ subpopulation. Stemness signature of CD133þ GBM cells was identified using microarray analysis. Stem cell potency, tumori-
genicity and drug resistance were also tested in differential expression of SOX2 in GBM cells.
Results: In this study, high tumorigenic and drug resistance was noticed in primary CD-133þ GBM cells; meanwhile, plenty of embryonic stem
cell markers were also elevated in the CD-133þ subpopulation. Using microarray analysis, we identified SOX2 as the most enriched gene among
the stemness signature in CD133þ GBM cells. Overexpression of SOX2 consistently enhanced the stem cell potency in the GBM cell lines,
whereas knockdown of SOX2 dramatically withdrew CD133 expression in CD133þ GBM cells. Additionally, we silenced SOX2 expression
using RNAi system, which abrogated the ability of tumor initiation as well as drug resistance of CD133þ GBM cells, suggesting that SOX2 plays
a crucial role in regulating tumorigenicity in CD133þ GBM cells.Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.
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539W.-S. Song et al. / Journal of the Chinese Medical Association 79 (2016) 538e545Conclusion: SOX2 plays a crucial role in regulating tumorigenicity in CD133þ GBM cells. Our results not only revealed the genetic plasticity
contributing to drug resistance and stemness but also demonstrated the dominant role of SOX2 in maintenance of GBM CSCs, which may
provide a novel therapeutic target to overcome the conundrum of poor survival of brain cancers.
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Glioblastoma multiforme (GBM) is a common, malignant
form of high-grade glioma. Despite treatment, prognosis is
still very poor within 12 months from diagnosis of GBM.1 In
addition, neurological symptoms such as epilepsy and neural
dysfunction have serious consequences for patients' quality of
life. Understanding the molecular mechanisms of disease
progression and chemoradioresistance in GBM is crucial for
developing therapeutic approaches and improving patient
survival.2,3 Currently, the first-line treatment of newly diag-
nosed GBM is surgical resection to the greatest extent fol-
lowed by adjuvant chemo- or radiotherapy. However, tumor
relapse commonly occurs within months following adjuvant
therapy. Some studies suggested that cancer stem cells (CSC)
are key contributors to therapeutic resistance and are thought
to be responsible for GBM progression as well as recurrence
after conventional therapy. Accumulated evidence indicates
only a subset of GBM cancer cells are able to proliferate
extensively, whereas most cancer cells only show a limited
ability for proliferation.4,5 Also, some studies further demon-
strate that the characteristics of stem cells originating from
CSCs exhibit a self-renewing capacity and are suggested to be
responsible for tumor heterogeneity, maintenance and metas-
tasis.6,7 It has been recently shown that CSCs are responsible
for the formation and growth of neoplastic tissue and are
resistant to chemotherapy, explaining why traditional chemo-
therapies fail to fully eradicate the tumor mass and recurrence
occurs. The method of CSC isolation from solid tumors has
been well-established through three distinct methodologies
based on the properties of CSC.8,9 CD133 (also known as
prominin-1), a membrane protein, has long been linked to
glioblastoma CSC isolation. Despite CD133 having first been
identified from hematopoietic stem cells and the function of
CD133 not yet having been uncovered, isolation via CD133 is
still broadly used for the isolation of CSCs due to its rapid and
efficient advantages using magnetic-activated cell sorting
(MACS). Some reports mentioned that chemotherapy as well
as radiotherapy increased the proportion of CSCs.10,11 The
results demonstrated that CD133-expressing CSCs from brain
tumors play a critical role not only in the restoration of tumor
cells and CSCs but also in resistance to radiotherapy.12,13
Although the role of CD133 in brain tumor cells is not fully
characterized, early data suggest that the CD133-positive
(CD133þ) subpopulation of brain tumor cells may be an
important target for optimizing brain tumor treatment through
radiotherapy.Sox2, a well-known marker of embryonic stem cells, is
critical for maintaining the self-renewing properties of stem
cells and is used for somatic cell reprogramming.14,15 Abun-
dant Sox2 expression has been linked to the maintenance of
CSC properties in glioma and medulloblastoma.16,17
Remarkably, glioblastoma stem cells have high Sox2 expres-
sion, while Sox2 knockdown forfeits the tumorigenicity and
stemness in glioma CSCs.16 Sox2 has been proven to regulate
self-renewal and proliferation in neural stem cells, and is
crucial in embryonic development. Therefore, investigation of
the regulation of Sox2-associated drug resistance is important.
In this study, we had three different but interconnected
aims: (1) elucidation of the role of Sox2 targeting pathways in
GBM and GBM-CSC; (2) identification of the novel CD133/
Sox2 regulatory axis; and (3) investigation of Sox2-mediated
oncogenic, cytoprotective signaling pathway, as well as the
drug resistance mechanism. We have identified the significant
role of CD133 in regulating GBM malignancy, and further
identified Sox2 as one of CD133 downstream targets which
promote self-renewal in GBM-derived stem cells. Thus, the
results of this study could be an interpretation of the role of
CSCs in radio-resistance and the oncogenic properties of
GBM, and could provide important information for developing
novel therapeutic strategies against GBM-CSCs.
2. Methods2.1. Cell lines and treatmentPrimary GBM cells, clone 1 and clone 2, were isolated
from GBM patients following surgery and written informed
consent was provided. Briefly, sterile scissors were used to cut
the tumor into small pieces and dissociate tissue using colla-
genase IV for 1 hour. Then the primary cells were seeded on
75 cm2 flask in DMEM/F12 medium plus glutamate (5 mmol/
L) and 10% fetal bovine serum. Cells were replaced with fresh
medium twice a week and incubated at 37oC in 5% CO2. Both
GBM primary clones were cultured over 10 selective passages.2.2. Isolation and culture of glioblastoma-derived
CD133þ cellsThis study was conducted according to the tenets of the
Declaration of Helsinki, and all samples were acquired after
patients provided informed consent. All cells in samples were
dissociated using trypsin and labeled with 1 mL CD133/l
micromagnetic beads per 1 million cells following the
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CA, USA). The sorted CD133þ CSCs were maintained in a
serum-free medium culture system, which contained DMEM/
F12 (Gibco-BRL, Gaithersburg, MD), N2 supplement (R&D
Systems, Inc., Minneapolis, MN, USA), 20 ng/ml human re-
combinant bFGF (R&D Systems) and 20 ng/ml EGF (R&D
Systems). CD133-negative (CD133) cells were cultured in
DMEM medium with 10% fetal bovine serum and glutamate
(5 mmol/L) added. The expression of CD133 surface markers
was determined by flow cytometry. Briefly, 1  105 cells were
suspended in 100 mL of phosphate-buffered saline (PBS) with
5mL anti-human CD133 antibody (Miltenyi Biotec, Bergisch
Gladbach, Germany) and chilled on ice for 15 minutes. After
washing two times with PBS, cells were resuspended in
100 mL of PBS, and analyzed with a FACSCalibur (Becton-
Dickinson, San Jose, CA, USA).18e212.3. Lentiviral-mediated RNA interferenceLentiviral backbone-Sox2 short hairpin RNA (shRNA) was
purchased from the National RNA interference Core Facility,
Academia Sinica, Taiwan. All the plasmids were separately
transfected into 293T cells, and the validation of expression of
Sox2 in protein level was estimated by Western blotting. The
shSox2-lentivirus was generated by transfection of 293T cells
using Lipofectamine 2000 (LF2000, Invitrogen, Carlsbad, CA,
USA), with supernatants obtained after 48 hours transfection.
This resulted in 80% of the confluent cells being infected with
lentivirus in the presence of 8 mg/ml polybrene (Sigma-
Aldrich, St. Louis, MO, USA) in the virus soup.2.4. Immunofluorescent stainingSamples were fixed in 4% paraformaldehyde for 15 minutes
on ice then washed three times with PBS. Blocking and anti-
body dilution buffer used PBS containing 5% normal goat
serum. The anti-Sox2 and anti-CD133 antibodies were added at
a dilution of 1:200 in antibody dilution buffer. After incubation
overnight at 4C, samples were washed with PBS three times.
The fluorescein isothiocyanate-labeled and allophycocyanin-
labeled secondary antibodies were added to the samples for
1 hour and washed twice with PBS. Then, Hoechest 33342 was
treated for 10 minutes to label the nuclear and mounted samples
by an antifade solution (Dako Corp., Carpinteria, CA, USA).
Slides were observed and analyzed using a confocal fluores-
cence microscope (Leica Microsystems, Wetzlar, Germany).
Images were captured using a Photometrics Sensys CCD
camera (Roper Scientific, Tucson, AZ, USA).2.5. Quantitative real-time reverse-transcriptase-
polymerase chain reactionThe quantitative reverse-transcriptase-polymerase chain
reaction (RT-PCR) followed previously described procedures,
and cDNAwas obtained from each sample which was reverse-
transcribed by Superscript II RT (Invitrogen). The primersequences used in this study were Oct4: F: GTGGA-
GAGCAACTCCGATG, R: TGCTCCAGCTTCTCCTTCTC;
Klf4: F: CCGCTCCATTACCAAGAGCT, R: ATCGTCTTCC
CCTCTTTGGC; Nanog: F: ATTCAGGACAGCCCTGATTC
TTC, R: TTTTTGCGACACTCTTCTCTGC; Sox2: F: CGA
GTGGAAACTTTTGTCGGA, R: TGTGCAGCGCTCGCAG.
The amplification was performed using LightCyclereFastStart
DNA Master SYBR green I (Roche Molecular Systems,
Alameda, CA, USA). PCRs were incubated at 95C for
10 minutes, then denatured at 95C for 10 seconds, annealed at
55C for 5 seconds, and extended at 72C for 20 seconds
followed by 40 cycles. All reactions followed the rule of
standard curves of cycle threshold values versus template
concentrations, then each target gene was compared with the
endogenous reference (GAPDH) in each sample. Data analysis
was quantified by LightCycler Relative Quantification Soft-
ware version 3.3 (Roche Molecular Systems).222.6. Western blot assayIn this study, protein extraction and Western blot procedure
were done as previously reported.20 Briefly, the prepared
protein samples were added to protein sample buffer and
heated at 95oC for 5 minutes. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis was used by loading
40 mg of protein extracted from each sample, then the wet-
transfer system was used to transfer the protein to Hybond-
electrochemiluminescence (ECL) nitrocellulose paper
(Amersham, Arlington Heights, IL, USA). The primary anti-
bodies used were rabbit anti-human Sox2 (1: 2000) and mouse
anti-ß-actin (1:5000) (Chemicon, Temecula, CA, USA). ECL
chromatography was detected by the ECL detection system
(Amersham Biosciences Co., Piscataway, NJ, USA).2.7. In vivo tumor modelSix-week-old female nude mice were used in this research.
The mice were caged in groups of five or less. Animals were
fed a diet of animal food and water ad libitum. All surgical
procedures followed the institutional animal welfare guide-
lines of Taipei Veterans General Hospital. CD133þ, CD133
and other treated cells were dissociated by trypsin, and cells
were counted in different cell dosages separately. Cells were
then suspended in 5 mL PBS and injected at 3 mm to the right
of the bregma in the brain using a Hamilton syringe. Further,
we cleaned the surface of the wound with sterile cotton and
filled the injection hole with bone wax after injection. All mice
with orthotopic brain tumors were measured for tumor size
every week.2.8. Statistical analysisAll results are shown as mean ± SD, and statistical analysis
was performed using a Student t test, one- or two-way analysis
of variance test followed by Tukey's test, as appropriate. A p
value <0.05 was considered statistically significant.
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GBM cell linesUsing magnetic beads,18 we successfully isolated CD133þ
cells from GBM cell lines (Fig. 1A). We subsequently
examined the mRNA levels of “stemness” genes (Oct-4/
Nanog/Sox-2/KLF-4) by real-time RT-PCR and found that
these “stemness” genes were up-regulated in GBM-CD133þ
as compared to GBM-CD133e (Fig. 1C). It has been reported
that tumor initiating cells can be cultured in suspension to
generate floating spheroid bodies (SB) that maintain their self-
renewal capabilities in serum-free media with bFGF and
EGF.23,24 We further evaluated the chemo- and radiation-
resistant abilities of CD133þ and CD133. When compared
with CD133, CD133þ was significantly resistant to cisplatin
(Fig. 1D; p < 0.01) and VP-16 (Fig. 1E; p < 0.01) in the in-
dividual clones isolated from GBM cell lines. As shown in
Fig. 1F, after 2 Gy ionizing radiation treatment, the survival
rate and number of CD133þ were significantly higher than
those of CD133 ( p < 0.01; Fig. 1F). These data support our100 101 102
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Fig. 1. Isolation and characterization of CD133þ tumor initiating cells from primary
cytometry using magnetic beads. (B) The morphological difference between CD13
mRNA expression level of stemness genes (Oct4, Klf4, Nanog and Sox2) in CD133
CD133þ GBM cells was increased after cisplatin and VP-16 treatment for 24 ho
CD133þ and CD133 GBM cells was analyzed by colony formation assay. (Clone 1
positive; CD133 ¼ CD133-negative; GBM ¼ glioblastoma multiforme.observation that GBM-CD133þ tumor initiating cells possess
a higher degree of radio-chemoresistance.3.2. Detection of high Sox2 expression in isolated
CD133þ cells from GBM cell linesTo further identify the systemic differential gene expression
profile in GBM-CD133þ, we performed a literature-based
network analysis of all MEDLINE records (title and ab-
stract) and used Cytoscape software (NIGMS, Bethesda, MD,
USA) to group the target-linkage genes from our microarray
data using a natural language processing regimen for gene and
protein names. This analysis successfully identified literature-
based network genes that were involved in stemness signa-
tures, and Sox-2-related pathway in GBM-CD133þ as opposed
to GBM-CD133e (Fig. 2A). To further address the regulatory
pathways, we dissected the network shared by Sox2 as well as
CD133 (also known as PROM1) and demonstrated a close
relationship between the duos using Cytoscape. Upon the
knowledge-based data mining, we noticed that Sox2 and
CD133 are closely connected through a bunch of stemness
genes including LIN28B, OCT4 (a.k.a. POU5F1), and several0
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GBM cell lines. (A) Population of CD133þ GBM cells was estimated by flow
3þ and CD133e GBM cells are shown (scale bar represents 100 mM). (C) The
þ GBM cells as compared with CD133 GBM cells. (D, E) The survival rate of
urs compared with CD133e GBM cells. (F) The effect of radio-resistance in
and clone 2 were collected from different GBM patients.). CD133þ ¼ CD133-
Fig. 2. A simplified scheme of Sox2-related pathway in GBM-CD133þ cells as opposed to GBM-CD133e with systems biology analysis. (A) Literature-based
network analysis to group the target-linkage genes from our microarray data using a natural language processing regimen for gene and protein names. This
analysis successfully identified literature-based network genes that were involved in stemness signatures, and Sox-2-related pathway in GBM-CD133þ as opposed
to GBM-CD133. (B) The expression and the knowledge-based data mining presence of GBM-CD133þ cells was directly correlated with LIN28, Sox2, POU5F1,
STAT3 and SMAD2/3. Lines indicate co-citation in the literature in more than one article. CD133þ ¼ CD133-positive; CD133 ¼ CD133-negative;
GBM ¼ glioblastoma multiforme.
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factors (Fig. 2B). Furthermore, we aligned the literature-based
network along a signaling cascade trend, which clearly dis-
played that Sox2 coordinately regulated the stemness with
CD133 (Fig. 2B).
The results of this literature linkage analysis support the
microarray data, which suggest that Sox2-axis pathway
expression is involved in the activation of anti-apoptosis and
cell migration-related gene clusters (Fig. 2). Furthermore,
using immunofluorescence assays, we detected high expres-
sion levels of Sox-2 protein in GBM-CD133þ (Fig. 3A) as
compared to CD133 cells ( p < 0.01; Fig. 3B). In accordance
with the systemic analysis, our immunofluorescence assay
detected high levels of Sox2 in GBM-CD133þ from two pa-
tients with GBM, but not in GBM-CD133 (Fig. 3). Taken
together, these data suggested that Sox2, an embryonic stem
cell marker, is highly expressed in GBM CSCs, as well as
highly correlated with CD133 surface in CSCs.3.3. The significance of Sox2 in GBM and GBM stem
cellsTo address whether Sox2 plays a role in maintaining self-
renewal or in regulating glioma stem-like properties in
GBM, we assessed the CSC-GBM cells' derived SB formation
ability and CD133 surface marker expression (Fig. 4). Firstly,we performed the gene silencing method using the short
interfering RNA system with lentiviral vector for knockdown
of Sox2 expression in GBM-CD133þ. We found it important
that the treatment of Sox2 shRNA in GBM-CD133þ signifi-
cantly inhibited the ability for SB formation ( p < 0.001;
Fig. 4A). The result of Western blotting showed the treatment
of Sox2-shRNA effectively blocked Sox2-protein expression
in GBM-CD133þ (Fig. 4B), confirming the suppressive effi-
cacy of Sox2-shRNA. Furthermore, after 14 days of treatment
with Sox2 shRNA, the SB of GBM-CD133þ could not
maintain floating spheres, and proliferation ability under stem
cell culture medium was significantly suppressed. Moreover,
the treatment of control shRNA with lentiviral vector did not
affect the Sox2-protein expression (Fig. 4B) and sphere-
formation ability in GBM-CD133þ (Fig. 4A and C).
Notably, the results of FASC-flow cytometry demonstrated
that the expression levels of CD133 were significantly
inhibited in Sox2 shRNA-treated GBM-CD133þ and the per-
centages of GBM-CD133e were dramatically elevated in
GBM-CD133þ, which was treated with Sox2 shRNA for
14 days after infection ( p < 0.001; Fig. 4D). Coordinately, the
in vivo limited dilution xenograft assay revealed that the
knockdown of Sox2 by shRNA dramatically eliminated the
tumorigenicity of CD133þ GBM CSCs (Table 1). These data
indicated that Sox2 may maintain the self-renewal and further
regulate cancer stem-like properties in malignant glioma.
Fig. 3. The significant expression of Sox2 in GBM and GBM stem cells. (A) The localization of CD133 and Sox2 was identified by immunofluorescence in
CD133þ GBM cells. (B) The quantitative expression levels of Sox2 protein in CD133þ and CD133 GBM cells were analyzed by imaging analysis software.
CD133þ ¼ CD133-positive; CD133 ¼ CD133-negative; GBM ¼ glioblastoma multiforme.
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Fig. 4. The regulation of CSC properties by Sox2. (A) Phase-contrast images of tumor sphere in parental, scramble control and Sox2 knockdown CD133þ GBM
cells are shown (scale bar means 100 mM). (B) The protein expression of Sox2 and beta-actin in parent, scramble control and Sox2 knockdown CD133þ cells were
estimated by Western blot. (C) Sox2 knockdown in CD133þ GBM cells decreased the sphere formation ability as compared with parental and scramble control of
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543W.-S. Song et al. / Journal of the Chinese Medical Association 79 (2016) 538e5454. Discussion
CSCs have been largely discussed with regard to their
characteristics and the methodologies used to isolate tumor
cells from malignant cancers. Considering the heterogeneity of
the tumor burden, diverse approaches have been developed to
isolate different subpopulations of CSCs. CD133 has beenwell-characterized as a markable surface marker for several
tumor stem cells, including these of leukemia, lung cancer,
hepatic cancer, gastric cancer, breast cancer and brain
tumor.25e29 Therefore, techniques using fluorescence-
activated cell sorting and MACS have been developed to
efficiently isolate CSCs, including CD133þ cancer cells, from
a bunch of tumor cells. Secondly, the side population of tumor
Table 1
Analysis of tumorigenic abilities in CD133þ/ cells isolating from GBM
clones.
Injected
number of cells
CD133 CD133þ CD133þ/si
RNA
CD133þ/si
Sox2
Clone 1 100,000 0/3 3/3 3/3 0/3
10,000 0/3 3/3 3/3 0/3
3000 0/3 2/3 3/3 0/3
Clone 2 100,000 0/3 3/3 3/3 0/3
10,000 0/3 3/3 3/3 0/3
3000 0/3 3/3 2/3 0/3
CD133þ ¼ CD133-positive; CD133 ¼ CD133-negative; GBM ¼
glioblastoma multiforme.
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resistance, significantly displays intracellular Hoechst 33342
exclusion in isolated CSCs.30 Expression of ABC transporter,
including ABCG2, an ATPase transporter, is closely associated
with the side population phenotype and drug-resistant abili-
ties.31,32 Thirdly, sphere formation is enriched in CSCs under
the inoculation of defined serum-free medium with growth
factors from individual solid tumors, primary tumor cells, or
cancer cell lines.33e36 Each method for CSC isolation con-
tributes to a different phenotype, but are all prone to tumor
initiation, tumor metastasis and drug resistance. In this study,
we demonstrated that MACS was used to quickly obtain GBM
CSCs via CD133 expression, which may acquire a different
subpopulation compared to side population, which can directly
indicate drug resistance regarding the rapid drug efflux
through ABC transporters. Indeed, our results concomitantly
showed that CD133þ GBM CSCs demonstrate a high ability
for drug-resistance. In addition, activation of the Hedgehog-
Gli1 pathway has been identified in a population of chemo-
radioresistant glial tumor cells, known as CSCs-CD133þ.37
These CSCs-CD133þ are resistant to current treatment mo-
dalities, such as radiation and temozolomide-based chemo-
therapy.38 Xenografts in immunocompromised mice were
significantly blocked by shRNA targeting Sox2. Coherently,
knockdown of Sox2 significantly suppressed the sphere for-
mation ability and side population percentage (Fig. 4). These
data suggested that Sox2 is important for both tumorigenicity
and drug resistance in CD133-isolated GBM stem cells.
Sox2, one of the neural stem cell markers, is a key member
of the transcriptional regulatory network that regulates plu-
ripotency and self-renewal of stem cells. Sox2 has also been
found to express in various tumor tissues, including lung
cancers, colorectal cancers, and pediatric brain tumors.39,40
Importantly, Gangemi et al demonstrated that tumor initi-
ating ability could be diminished through silencing Sox2
expression in freshly derived glioblastoma tumor-initiating
cells. They further suggested that silenced Sox2 GBM
tumor-initiating cells would stop proliferating and lose
tumorigenicity in immunosuppressant mice.15 Furthermore,
Yang et al showed that the knockdown of the SOX2 gene in the
GBM cell line (LN229) reduces cellular proliferation and
colony formation.41 Interestingly, we found a putative
connection between CD133 and Sox2 using bioinformatics
analysis (Fig. 2). Notably, several stemness gene signatureswere involved, as well as proliferation-related genes, sug-
gesting that crosstalk between the duos is required for CSC
properties.
In conclusion, our results suggest that Sox2 plays a critical
role in the carcinogenesis and maintenance of GBM stem
cells, which greatly contribute to resistance to therapies
including chemotherapy and radiotherapy. Here, we have
illustrated a new regulatory axis of CD133-Sox2 coordinates
to the enrichment of CSCs from brain tumors. Thus, CD133-
Sox2 can be a suitable target for new therapeutics in a cura-
tive intent aimed at GBM in the coming era.
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